Get the Stockscreener App
39.92
0.68%
0.27
After Hours:
39.92
Moonlake Immunotherapeutics stock is traded at $39.92, with a volume of 447.90K.
It is up +0.68% in the last 24 hours and down -4.73% over the past month.
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
See More
Previous Close:
$39.65
Open:
$39.45
24h Volume:
447.90K
Relative Volume:
1.24
Market Cap:
$2.53B
Revenue:
-
Net Income/Loss:
$-80.77M
P/E Ratio:
-31.43
EPS:
-1.27
Net Cash Flow:
$-80.80M
1W Performance:
+1.55%
1M Performance:
-4.73%
6M Performance:
-25.67%
1Y Performance:
-21.09%
1-Day Range:
$39.33
$40.35
1-Week Range:
$37.70
$40.98
52-Week Range:
$36.52
$58.26
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Name
Moonlake Immunotherapeutics
Sector
Industry
Phone
41 41 510 8022
Address
DORFSTRASSE 29, ZUG
Compare MLTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
39.92 | 2.53B | 0 | -80.77M | -80.80M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-17-25 | Upgrade | Goldman | Neutral → Buy |
| Nov-05-24 | Resumed | Wedbush | Outperform |
| Aug-26-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Initiated | Oppenheimer | Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Citigroup | Buy |
| Nov-02-23 | Initiated | Stifel | Buy |
| Sep-14-23 | Downgrade | Bryan Garnier | Buy → Neutral |
| Aug-31-23 | Initiated | Needham | Buy |
| Jun-15-23 | Initiated | Barclays | Equal Weight |
| May-01-23 | Initiated | Guggenheim | Buy |
| Mar-22-23 | Initiated | Wedbush | Outperform |
| Mar-09-23 | Initiated | BTIG Research | Buy |
| Feb-14-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-02-23 | Initiated | Bryan Garnier | Buy |
| Nov-11-22 | Initiated | Jefferies | Buy |
| Aug-25-22 | Initiated | SVB Leerink | Outperform |
| Jul-21-22 | Initiated | H.C. Wainwright | Buy |
| Jul-07-22 | Initiated | Cowen | Outperform |
View All
Moonlake Immunotherapeutics Stock (MLTX) Latest News
MoonLake Immunotherapeutics’ Sonelokimab Positioned as Leading Treatment for Hidradenitis Suppurativa Amidst Weak JAK Inhibitor Competition - TipRanks
BTIG maintains Moonlake stock Buy rating and $81 target - Investing.com
BTIG maintains Moonlake stock Buy rating and $81 target By Investing.com - Investing.com UK
MoonLake earns new Outperform at RBC Capital Markets on lead drug - MSN
RBC Capital Initiates Coverage of MoonLake Immunotherapeutics (MLTX) with Outperform Recommendation - Nasdaq
MoonLake stock earns new Outperform at RBC (MLTX:NASDAQ) - Seeking Alpha
Why MoonLake Immunotherapeutics Shares Are Rising - TipRanks
Guggenheim maintains $80 target on Moonlake Immunotherapeutics stock - Investing.com
MoonLake Immunotherapeutics initiated with an Outperform at RBC Capital - TipRanks
RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target - Marketscreener.com
MoonLake Immunotherapeutics: Advancing Sonelokimab with Promising Phase III VELA Program and Favorable Market Positioning - TipRanks
MoonLake Immunotherapeutics Advances Clinical Trials in 2024 - TipRanks
MoonLake’s CEO on its looming mid-year pivotal readout in skin disease - Endpoints News
Cowen maintains Buy on Moonlake Immunotherapeutics stock By Investing.com - Investing.com Australia
Cowen maintains Buy on Moonlake Immunotherapeutics stock - Investing.com India
MoonLake Immunotherapeutics: Promising Prospects for Sonelokimab in Inflammatory Diseases - TipRanks
Why MoonLake Immunotherapeutics is the Dark Horse Pharma Stock to Watch in 2025 - DSA
Optimistic Outlook for MoonLake Immunotherapeutics: Promising Developments and Market Opportunities for Sonelokimab - TipRanks
MoonLake Immunotherapeutics (NASDAQ:MLTX) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
The Goldman Sachs Group Cuts MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $73.00 - Defense World
Brokers Offer Predictions for MLTX Q2 Earnings - MarketBeat
MoonLake Immunotherapeutics (MLTX) Projected to Post Earnings on Thursday - MarketBeat
(MLTX) Technical Pivots with Risk Controls - Stock Traders Daily
The Goldman Sachs Group Has Lowered Expectations for MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price - MarketBeat
MoonLake Immunotherapeutics' (MLTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Needham & Company LLC Increases MoonLake Immunotherapeutics (NASDAQ:MLTX) Price Target to $66.00 - MarketBeat
MoonLake Immunotherapeutics (NASDAQ:MLTX) Issues Earnings Results, Misses Expectations By $0.09 EPS - MarketBeat
MoonLake Immunotherapeutics: Buy Rating Backed by Promising SLK Data and Strong Financial Position - TipRanks
MoonLake Immunotherapeutics (MLTX) to Release Quarterly Earnings on Thursday - Defense World
Buy Rating for MoonLake Immunotherapeutics Driven by Promising Clinical Programs and Market Potential - TipRanks
Moonlake Immunotherapeutics Faces Hurdles in Commercializing SLK Despite Potential Approvals - TipRanks
MoonLake Immunotherapeutics: Strong Buy Rating Amid Promising Phase 3 Trials and Robust Financial Position - TipRanks
Buy Rating for MoonLake Immunotherapeutics: Strong Financials and Promising Clinical Developments - TipRanks
MoonLake Immunotherapeutics: Promising Future with Strong Financial Position and Clinical Advancements - TipRanks
MoonLake Immunotherapeutics reports Q4 EPS (72c), consensus (59c) - TipRanks
MoonLake Immunotherapeutics Q4 Loss Widens -February 26, 2025 at 07:53 am EST - Marketscreener.com
Earnings Flash (MLTX) MoonLake Immunotherapeutics Posts Q4 Loss of $-0.72 a Share, vs. FactSet Est of $-0.59 Loss - Marketscreener.com
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - The Manila Times
MoonLake Immunotherapeutics SEC 10-K Report - TradingView
Is MoonLake Immunotherapeutics (MLTX) An Oversold Biotech Stock to Buy Now? - Insider Monkey
This MoonLake Immunotherapeutics Insider Reduced Their Stake By 50% - Simply Wall St
MoonLake Immunotherapeutics (MLTX): the Most Oversold Pharma Stock to Buy According to Analysts - Insider Monkey
10 Oversold Pharma Stocks to Buy According to Analysts - Insider Monkey
Congress Asset Management Co. Raises Stock Position in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? - MSN
Rice Hall James & Associates LLC Raises Holdings in MoonLake Immunotherapeutics (NASDAQ:MLTX) - MarketBeat
Will MoonLake Immunotherapeutics Lead Healthcare Stocks’ Resurgence? - DSA
Why MoonLake Immunotherapeutics Could Be the Next Big Bet in Healthcare - MotoPaddock
MoonLake Immunotherapeutics (MLTX): Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
(MLTX) Proactive Strategies - Stock Traders Daily
Moonlake Immunotherapeutics Stock (MLTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):